αvβ5 Integrin

αvβ5 integrin is a cell-surface protein made of two subunits (alpha-v and beta-5) that helps cells attach to surrounding tissue and respond to mechanical and chemical signals. It is found on many cell types, including the mesothelial cells that line the chest and abdominal cavities, and it plays a role in how those cells take up asbestos fibers and respond to injury. In mesothelioma research, αvβ5 has been studied as a contributor to tumor cell survival, invasion, and the inflammatory response that follows asbestos exposure.

Origin

Integrins were identified and named in the mid-1980s by Richard Hynes and colleagues, who recognized this family of receptors as the molecules that 'integrate' the cell's internal skeleton with the extracellular matrix. The αvβ5 pairing was characterized shortly afterward as one of several alpha-v integrins that bind matrix proteins containing an RGD (arginine-glycine-aspartate) sequence, such as vitronectin.

Significance in Asbestos Context

Laboratory studies have shown that mesothelial cells use αvβ5 integrin, together with other receptors, to engulf long asbestos fibers, a process that contributes to chromosomal damage and the chronic inflammation believed to drive mesothelioma. In established mesothelioma tumors, αvβ5 is often expressed at higher levels and is linked to cell migration, resistance to cell death, and interaction with the tumor microenvironment. For patients, this matters because αvβ5 is one of several molecular targets under investigation for newer therapies, including drugs that block integrin signaling and antibody-drug conjugates being tested in clinical trials. Pathology reports and research-based tumor profiling may mention integrin expression when discussing experimental treatment options.

Example Sentence

When the oncologist explained why fiber length matters biologically, she pointed to research showing that αvβ5 integrin on mesothelial cells helps pull long asbestos fibers into the cell, where they cause genetic damage over many years.

Related Terms

Mesothelial Cells, Frustrated Phagocytosis, Tumor Microenvironment, HMGB1, Chronic Inflammation, Molecular Targeted Therapy

Notes

• If you are considering a clinical trial, ask whether the trial involves integrin-targeted therapy or molecular profiling of your tumor, and whether αvβ5 expression is measured.
• Request a copy of any molecular or immunohistochemistry testing performed on your tumor tissue; integrin and related markers may appear in extended panels.
• Ask your treating oncologist whether your tumor block has been preserved and whether additional research-based testing (including integrin expression) is available through an academic mesothelioma center.
• Keep records of any experimental or targeted therapies you receive. These can be relevant both to your medical care and to documenting the biological basis of asbestos-caused disease in your claim.